Target Name: WDR54
NCBI ID: G84058
Review Report on WDR54 Target / Biomarker Content of Review Report on WDR54 Target / Biomarker
WDR54
Other Name(s): WDR54 variant 3 | WD repeat domain 54, transcript variant 3 | FLJ12953 | WD repeat domain 54 | WD repeat-containing protein 54 | WDR54_HUMAN | WD repeat-containing protein 54 (isoform b)

WDR54: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker

WDR54, also known as WDR54 variant 3, is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. WDR54 is a key regulator of the DNA damage response, a critical pathway that protects the cell from DNA damage caused by various factors such as radiation, viruses, and chemicals.

The DNA damage response is a complex process that involves multiple proteins working together to repair damaged DNA. WDR54 plays a crucial role in this process by ensuring that the repair machinery is properly assembled and that the damaged DNA is correctly modified to prevent future damage.

WDR54 is a small RNA molecule that contains only about 200 amino acid residues. It is primarily expressed in the cytoplasm of the cell and is also found in the endoplasmic reticulum. WDR54 has been shown to play a role in regulating the DNA damage response by ensuring that the repair machinery is properly assembled and that the damaged DNA is correctly modified.

One of the most significant findings related to WDR54 is its role in the development of cancer. Several studies have shown that high levels of WDR54 are associated with an increased risk of cancer. For example, a study by the National Cancer Institute found that individuals with The surname Chen has a higher incidence of cancer and is also more likely to have high levels of WDR54.

Another study by the University of California, Irvine found that individuals with certain genetic mutations, such as those in the TP53 gene, are also more likely to have high levels of WDR54. The TP53 gene is a well-known gene that plays a critical role in regulating the DNA damage response.

WDR54 has also been shown to be involved in the regulation of cellular processes such as cell growth, apoptosis, and autophagy. For example, a study by the University of California, San Diego found that WDR54 plays a role in regulating the autophagy process, a process by which cells break down and recycle damaged or unnecessary proteins.

In addition to its role in the DNA damage response and cancer development, WDR54 has also been shown to be involved in the regulation of cellular processes such as cell growth, apoptosis, and autophagy.

WDR54 has also been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and autophagy. For example, a study by the University of California, San Diego found that WDR54 plays a role in regulating the autophagy process, a process by which cells break down and recycle damaged or unnecessary proteins.

In conclusion, WDR54 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. Its role in the DNA damage response and cancer development, as well as its involvement in the regulation of cellular processes such as cell growth, apoptosis, and autophagy, make it an attractive target for further research. Further studies are needed to fully understand the role of WDR54 in these processes and to determine its potential as a drug.

Protein Name: WD Repeat Domain 54

Functions: When cross-linked to form dimers and trimers, it has a regulatory effect on ERK signaling pathway activity in response to EGF stimulation. Colocalizes with the EGF receptor in WDR54-specific vesicle where it sustains the internalization and controls the degradation of the EGF receptor after EGF stimulation

The "WDR54 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WDR54 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89 | WDR90 | WDR91 | WDR93 | WDR97 | WDSUB1 | WDTC1 | WEE1 | WEE2 | WEE2-AS1 | WFDC1 | WFDC10A | WFDC10B | WFDC11 | WFDC12 | WFDC13 | WFDC2 | WFDC21P | WFDC3 | WFDC5 | WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1 | WIPF1 | WIPF2 | WIPF3 | WIPI1 | WIPI2 | WIZ | WLS | WNK1 | WNK2 | WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B | WNT3 | WNT3A | WNT4 | WNT5A | WNT5B | WNT6 | WNT7A | WNT7B | WNT8A | WNT8B | WNT9A | WNT9B | WRAP53 | WRAP73 | WRN | WRNIP1 | WSB1 | WSB2 | WSCD1 | WSCD2 | WSPAR | WT1 | WT1-AS | WTAP | WTAPP1 | WTIP